Does Maca Sexual Function Randomized Trial work?

Updated October 2026

Quick Answer

Maca Sexual Function Randomized Trial has evidence relevant to strength of evidence and what the studies can or cannot prove, but conclusions should stay close to the cited sources. One representative finding is: It drives many physiological, emotional, and mental shifts that occur during this transition, including vasomotor symptoms, bone loss, alterations in body composition, changes in mood and cognition, and increased cardiometabolic risk [].

Key Takeaways

  • 01It drives many physiological, emotional, and mental shifts that occur during this transition, including vasomotor symptoms, bone loss, alterations in body composition, changes in mood and cognition, and increased cardiometabolic risk []. [Minich Deanna (2026)]
  • 0229 30 31 32 33 Historically, this rise with the transition from the reproductive to menopausal stage of life has been interpreted primarily as a compensatory response to declining ovarian function and reduced negative feedback from the ovaries []. [Minich Deanna (2026)]
  • 0334 35 36 37 34 38 39 40 Another point of consideration is the evidence accumulating for FSH’s actions beyond the ovary. [Minich Deanna (2026)]
  • 041 2 3 4 Over the past two decades, perimenopause and menopause have emerged as prominent topics in medical and public discourse. [Minich Deanna (2026)]
The current Migaku evidence database contains 1 reusable source document for Maca Sexual Function Randomized Trial. This answer focuses on strength of evidence and what the studies can or cannot prove. - It drives many physiological, emotional, and mental shifts that occur during this transition, including vasomotor symptoms, bone loss, alterations in body composition, changes in mood and cognition, and increased cardiometabolic risk []. [Minich Deanna (2026); evidence level 3] - 29 30 31 32 33 Historically, this rise with the transition from the reproductive to menopausal stage of life has been interpreted primarily as a compensatory response to declining ovarian function and reduced negative feedback from the ovaries []. [Minich Deanna (2026); evidence level 3] - 34 35 36 37 34 38 39 40 Another point of consideration is the evidence accumulating for FSH’s actions beyond the ovary. [Minich Deanna (2026); evidence level 3] - 1 2 3 4 Over the past two decades, perimenopause and menopause have emerged as prominent topics in medical and public discourse. [Minich Deanna (2026); evidence level 3] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.

Sources

  1. Is Follicle-Stimulating Hormone (FSH) Misnamed? Rethinking Its Role in Menopause as a Systemic Regulator of Bone, Brain, Metabolism, and Aging